Compare

Collagen Peptides vs Tirzepatide

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Collagen Peptides

1220 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 44% · Mixed 40% · Unfavorable overall 16%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Sleep quality
7
Lean mass
11
Joint comfort
-146
Recovery
-121
Digestive comfort
-73

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Water retention
-77
Appetite loss
-90
Injection site reaction
-1
Anxiety
-125
Flushing
-73

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 10–1000 mcg

10–25
3
25–50
10
50–100
12
100–200
17
200–400
9
400–600
10
600–1000
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing24stacking37side effects10collagen peptides28

How repeat users are trending

Among repeat reporters, 54% said they felt similar to their last entry, 36% more positive, and 14% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 34 days · Based on 268 repeat reporters

Tirzepatide

2335 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 49% · Mixed 36% · Unfavorable overall 15%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Lean mass
50
Joint comfort
106
Recovery
68
Digestive comfort
86
Skin appearance
88

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Appetite loss
146
Injection site reaction
186
Anxiety
33
Flushing
82
Headache
88

Self-reported dose per injection

Median bucket: 1–2 mg · Most common: 0.6–1 mg

Reports span 0.2–5 mg

0.2–0.4 mg
3
0.4–0.6 mg
13
0.6–1 mg
17
1–2 mg
9
2–3 mg
10
3–5 mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing19stacking27side effects15tirzepatide18

How repeat users are trending

Among repeat reporters, 59% said they felt similar to their last entry, 29% more positive, and 19% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 24 days · Based on 514 repeat reporters

Sources (14)

Published sources linked on the Collagen Peptides and Tirzepatide wiki pages.

  1. PubMed

    Oral intake of specific bioactive collagen peptides reduces skin wrinkles and improves dermal matrix synthesis

    Proksch E, Schunck M, Zague V, et al. Skin Pharmacol Physiol. 2014

    Source
    Wiki study page →
  2. PubMed

    Collagen supplementation for osteoarthritis: a systematic review and meta-analysis

    García-Coronado JM, Martínez-Olvera L, Elizondo-Omaña RE, et al. Int Orthop. 2019

    Source
    Wiki study page →
  3. PubMed

    Daily oral supplementation with collagen peptides combined with vitamins and other bioactive compounds improves skin elasticity and has a beneficial effect on joint and general wellbeing

    Czajka A, Kania EM, Genovese L, et al. Nutrition research (New York, N.Y.). 2018

    Source
    Wiki study page →
  4. FDA Drug Label

    MOUNJARO (tirzepatide) injection, for subcutaneous use - Prescribing Information

    Eli Lilly. FDA Drug Label. 2022

    Source
    Wiki study page →
  5. PubMed

    Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

    Jastreboff AM, Aronne LJ, Ahmad NN, et al. N Engl J Med. 2022

    Source
    Wiki study page →
  6. ClinicalTrials.gov

    Tirzepatide obesity studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  7. PubMed

    Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

    Frías JP, Davies MJ, Rosenstock J, et al. N Engl J Med. 2021

    Source
    Wiki study page →
  8. PubMed

    Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).

    Frias JP, De Block C, Brown K, et al. J Clin Endocrinol Metab. 2024

    Source
    Wiki study page →
  9. FDA Drug Label

    ZEPBOUND (tirzepatide) injection, for subcutaneous use - Prescribing Information

    Eli Lilly. FDA Drug Label. 2023

    Source
    Wiki study page →
  10. PubMed

    Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

    Garvey WT, Frias JP, Jastreboff AM, et al. Lancet (London, England). 2023

    Source
    Wiki study page →
  11. PubMed

    Tirzepatide for Obesity Treatment and Diabetes Prevention

    Jastreboff AM, le Roux CW, Stefanski A, et al. The New England journal of medicine. 2025

    Source
    Wiki study page →
  12. PubMed

    GLP-1 receptor agonist discontinuation and cardiovascular events and all-cause mortality in people with type 2 diabetes: a retrospective cohort study

    Ceriello A, Prattichizzo F, Lucisano G, et al. Lancet Reg Health Eur. 2026

    Source
    Wiki study page →
  13. PubMed

    Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

    Aronne LJ, Ahmad NN, Fletcher M, et al. JAMA. 2024

    Source
    Wiki study page →